Avinash Godara
About Avinash Godara
Avinash Godara is a Scientist II at Entrada Therapeutics, specializing in fermentation process development and metabolic engineering. He holds a Ph.D. in Chemical Engineering from Texas A&M University and has experience in high throughput screening and chromatography techniques.
Current Position at Entrada Therapeutics
Avinash Godara currently serves as Scientist II at Entrada Therapeutics, a role he has held since 2022. He is based in Boston, Massachusetts, United States. In this position, he continues to leverage his expertise in fermentation process development and scale-up, contributing to the company's research and development efforts.
Previous Experience at Entrada Therapeutics
Avinash Godara previously worked at Entrada Therapeutics as Scientist I from 2021 to 2022. During his 10-month tenure, he developed a microbial high throughput screening platform for strain development. His work focused on enhancing the efficiency of laboratory evolution strategies, which are critical for advancing biotechnological applications.
Educational Background
Avinash Godara completed his Doctor of Philosophy (Ph.D.) in Chemical Engineering at Texas A&M University from 2016 to 2021. His research concentrated on metabolic engineering of yeast for the production of high-value terpenes and carotenoids. He also holds a Dual Degree in Chemical Engineering from the Indian Institute of Technology, Delhi, where he studied from 2009 to 2014.
Internship Experience at Biocon
In 2012, Avinash Godara completed a two-month internship at Biocon in Bengaluru Area, India. This early experience provided him with foundational knowledge in biotechnology and reinforced his interest in the field.
Technical Expertise
Avinash Godara possesses a strong background in various chromatography techniques, including ion exchange, hydrophobic interaction, size exclusion, and affinity chromatography. He also specializes in CRISPR-Cas9 technology, molecular biology, and genetic engineering, which are essential for his current research initiatives.